

Pulmonary-Allergy Drugs Advisory Committee Meeting
November 8, 2022
Pre-recorded Presentations

Both the Food and Drug Administration (FDA) and Bond Avillion/AstraZeneca have prepared pre-recorded presentations for the November 8, 2022 Pulmonary-Allergy Drugs Advisory Committee meeting. These pre-recorded presentations will be viewed by the committee prior to the meeting and **will not be replayed on meeting day**.

The recordings of the presentations can be found at the following addresses:

FDA Presentations (listed in viewing order):

1. Introduction and Overview of Clinical Trials: NDA 214070: budesonide/albuterol sulfate metered dose inhaler for the as-needed treatment of asthma by Elisabeth Boulos, MD; Division of Pulmonology, Allergy, and Critical Care
(Part 1 of 3) - <https://collaboration.fda.gov/p037mvacexjb/>
2. Summary of Efficacy Results: NDA 214070: budesonide/albuterol sulfate metered dose inhaler for the as-needed treatment of asthma by Dong-Hyun Ahn, PhD; Division of Biometrics III
(Part 2 of 3) - <https://collaboration.fda.gov/pen2jme7gbje/>
3. Summary of Safety and Conclusions: NDA 214070: budesonide/albuterol sulfate metered dose inhaler for the as-needed treatment of asthma by Elisabeth Boulos, MD; Division of Pulmonology, Allergy, and Critical Care
(Part 3 of 3) - <https://collaboration.fda.gov/pxtnd7d56mpa/>

Bond Avillion/AstraZeneca Presentations:

1. Budesonide/Albuterol Sulfate Metered Dose Inhaler (BDA MDI) By Bond Avillion/AstraZeneca
(Part 1 of 1) - <https://collaboration.fda.gov/pg07yni6ra6q>

We recommend that you watch these pre-recorded presentations in “**Classic View**.” After opening any of the above links, click “**Switch**” when prompted by Adobe Connect to “**Switch to Classic View**.”

Your internet browser may require a plugin to playback these presentations. If your browser does not already have it installed, you may be prompted to download and install it.

The slides and transcripts of these pre-recorded presentations can be found at:
<https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-information-november-8-2022-meeting-pulmonary-allergy-drugs-advisory-committee-meeting>